ETFs positioned on Laboratorios Farmaceuticos Rovi, S.A.

Name YTD change Weight AuM
+15.15%-.--% 41,780 M€
+8.58%-.--% 1,193 M€
+11.17%-.--% 67 M€
+5.68%-.--% 49 M€
+1.41%-.--% 51 M€
-.--%0.51% 17 M€
+17.07%0.51% 111 M€
-.--%0.42% 48 M€
+6.53%0.42% 11 M€
+12.58%0.29% 701 M€
+10.84%0.29% 534 M€
+17.88%0.27% 542 M€
+8.95%0.24% 6 M€
+8.51%0.23% 458 M€
+10.95%0.23% 335 M€
+16.89%0.22% 558 M€
+11.03%0.22% 1,025 M€
+14.82%0.17% 81 M€
-.--%0.17% 258 M€
+8.84%0.14% 8 M€
-9.32%0.11% 336 M€
+10.15%0.11% 336 M€
+8.91%0.1% 579 M€
+8.07%0.09% 90 M€
+11.45%0.09% 241 M€
+11.73%0.09% 121 M€
+6.64%0.09% 184 M€
+8.51%0.07% 137 M€
+10.19%0.07% 170 M€
+9.85%0.06% 692 M€
+8.13%0.06% 1,501 M€
+11.09%0.05% 5,679 M€
+6.54%0.05% 730 M€
+10.99%0.05% 13,445 M€
+12.48%0.05% 258 M€
+10.60%0.05% 12,001 M€
+6.22%0.04% 270 M€
+8.43%0.04% 657 M€
+7.49%0.04% 759 M€
+7.88%0.04% 3 M€
+12.74%0.04% 19 M€
+18.61%0.04% 19,658 M€
+13.64%0.04% 901 M€
-20.91%0.04% 901 M€
+8.57%0.04% 2,233 M€
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
2,470
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. ETFs Laboratorios Farmaceuticos Rovi, S.A.